Alexander Vos (1962) has 20 years of leadership experience in the pharma and biotech industry. Following his graduate studies of pharmacy and pharmacology in Amsterdam, Netherlands, and at the Mayo Clinic in the United States, he obtained a MBA from Stanford University in the United States (1989). After completing his studies, Alexander Vos spent five years as a strategy consultant working for the international pharmaceutical practice of McKinsey & Co. He subsequently worked at Genzyme Therapeutics Europe, holding several executive positions such as European Marketing Director and Director of Business Development, before assuming global responsibility for the joint venture between Genzyme Corporation and Pharming NV, which pursued the goal of developing an innovative therapy for a genetic muscular disease. From 2000 to 2004, Mr. Vos served as Chief Executive Officer of MediService AG (Switzerland), one of the leading specialty pharmacy service companies in Europe, which was successfully sold to Galenica AG. Before joining PharmaCell, he worked for PAION AG, where he was a Member of the Management Board (“Vorstand”) and Chief Operating Officer. PAION is a clinical stage biopharmaceutical company based in Aachen (Germany) and Cambridge (UK) that is listed on the Frankfurt Stock Exchange.
Rene Lardenoije (1961) has started his career at the University of Leiden as researcher in the field of Cancer. Subsequently he joint Centocor where he held several positions at Quality Control and Product Development. As Manager Pilot Plant he was able to bring over 20 different antibodies into the clinic. At IntroGene he was responsible for the pharmaceutical development of the PER.C6 technology. As Director Pharmaceutical Production he and his team managed to be be one of the first companies in the world having a licensed GMP facility for the production of viral vectors. He was part of the team that changed IntroGene into Crucell. As Vice President Pharmaceutical Production he was responsible for all pharmaceutical development and operations related to the PER.C6 technology. After leaving Crucell, Rene founded his own consultant company Syntiro Pharma Support International. As a Consultant he advised clients in several pharmaceutical fields such as facility design and validation, implementing and improving quality systems, product and process development, quality control and regulatory compliance. Rene founded PharmaCell in early 2005.